← Leaderboards
Allen Bernard Reitz
Fox Chase Chemical Diversity Center, Inc
$17,179,193
Attributed
$18,687,072
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,687,072 · 9
By mechanism
U01$7,375,647 · 1
R44$6,419,411 · 2
R42$3,015,759 · 1
R43$1,276,255 · 3
R41$600,000 · 2
Top collaborators
- Robert Paul Ricciardi3 shared
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIn VivoPharmaceutical PreparationsAlzheimer&AposSmall MoleculePropertyCellsToxic EffectEvaluationProteinsMutantDoseSolubilityAmyotrophic Lateral SclerosisPenetrationBaseMetabolicHalf-LifeSafetyBindingPre-ClinicalDrug KineticsClinical TrialsRattus
Grant awards (23)
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,438,738
U01 · FY2025 · AG · contact PI
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,363,709
U01 · FY2024 · AG · contact PI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$975,748
R42 · FY2024 · AI · contact PI
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,365,008
U01 · FY2023 · AG · contact PI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$990,011
R42 · FY2023 · AI · contact PI
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,386,046
U01 · FY2022 · AG · contact PI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$1,050,000
R42 · FY2022 · AI · contact PI
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$409,375
U01 · FY2022 · AG · contact PI
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,412,771
U01 · FY2021 · AG · contact PI
Riluzole Prodrugs for Melanoma and ALS$1,000,000
R44 · FY2020 · CA · contact PI
Riluzole Prodrugs for Melanoma and ALS$1,000,000
R44 · FY2019 · CA · contact PI
Riluzole Prodrugs for Melanoma and ALS$1,000,000
R44 · FY2018 · CA · contact PI
PET Imaging Agents for the in vivo Detection of TDP-43$754,275
R44 · FY2018 · AG · contact PI
PET Imaging Agents for the in vivo Detection of TDP-43$745,412
R44 · FY2017 · AG · contact PI
DEVELOPMENT OF DRUGS THAT TARGET THE M2 PROTON CHANNEL FROM INFLUENZA A VIRUS$40,000
R43 · FY2016 · AI · contact PI
DEVELOPMENT OF DRUGS THAT TARGET THE M2 PROTON CHANNEL FROM INFLUENZA A VIRUS$300,000
R43 · FY2015 · AI · contact PI
Riluzole Prodrugs for Melanoma and ALS$959,604
R44 · FY2014 · CA · contact PI
Riluzole Prodrugs for Melanoma and ALS$960,120
R44 · FY2013 · CA · contact PI
New therapeutics for the treatment of Acinetobactor baumannii infections.$300,000
R41 · FY2013 · AI · contact PI
DC-SIGN Inhibitors for the Treatment of HIV Infection$300,000
R41 · FY2013 · AI · contact PI
Riluzole Prodrugs for Melanoma and ALS$336,255
R43 · FY2011 · CA · contact PI
Pathogen-Specific Regulation of Protein Assembly$300,000
R43 · FY2010 · AI · contact PI
Pathogen-Specific Regulation of Protein Assembly$300,000
R43 · FY2009 · AI · contact PI